Botanix Completes Enrolment of BTX 1503 Acne Patient Study
Filed with ASX · · 2 pages · English
Watch Botanix Pharmaceuticals' latest callBotanix Pharmaceuticals (ASX:BOT) Q2 2026 Earnings Call · Replay · Mar 2Read the transcript of Botanix Pharmaceuticals (ASX:BOT) Q2 2026 Earnings CallBotanix Pharmaceuticals Limited on 6ix
Story so far
Earlier from Botanix Pharmaceuticals
- New Antibacterial Results Support BTX 1503 Acne Program
- Botanix Enrols First Patients in Dermatitis Study
- Botanix Commences BTX 1204 Dermatitis Patient Study
- FDA Clears Development Path for BTX 1503
- Botanix Commences BTX 1503 Acne Patient Study
Later from Botanix Pharmaceuticals
- Botanix Receives A$1.6m R&D Tax Incentive Refund
- Botanix Announces Successful Acne Study Results
- Significantly Oversubscribed A$15m Placement
- Completion of Placement
- Enrolment of BTX 1204 Atopic Dermatitis Study Completed
Follow Botanix Pharmaceuticals into a list and get an email when it puts out news.
Follow Botanix Pharmaceuticals